Hongbo Lu, Ph.D., M.B.A.

Hongbo Lu is a Managing Partner at Vivo Capital. Prior to joining Vivo, Dr. Lu was a Managing Partner at Lilly Asia Ventures. Dr. Lu has over 20 years of investment and operational experience in healthcare industry. Dr. Lu currently serves on the board of directors of several private biotechnology companies, such as Ablaze Pharmaceuticals, Avistone Pharmaceuticals, Rgenta Therapeutics, Ribox Therapeutics, RareStone Group, Visirna Therapeutics and Zenas BioPharma. She previously served on the board of directors of public companies including Turning Point Therapeutics, Inc., a publicly-traded biotechnology company, from May 2017 to May 2019, and on the board of directors of Avedro, Inc., a publicly-traded biotechnology company, from May 2018 to February 2019.  She holds a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University.